Elsevier BV

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Bajorin
    Bajorin
  4. Carlo
    Carlo
  5. Feldman
    Feldman
  6. Morris
    Morris
  7. Rosenberg
    Rosenberg
  8. Voss
    Voss
  9. Abida
    Abida
  10. Benfante
    Benfante

Groups

  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
  4. Epidemiology and Biostatistics (5)
  5. Surgery (5)
  6. Urology (5)
  7. GSK Faculty (4)
  8. Weinberg Fellows (4)
  9. Biostatistics Service (3)
  10. Department of Pathology and Laboratory Medicine (3)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (15)
  2. Review (5)
Groups
  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
  4. Epidemiology and Biostatistics (5)
  5. Surgery (5)
  6. Urology (5)

More Groups

People
  1. Robert Motzer (6)
  2. Dean Bajorin (4)
  3. Howard Scher (4)
  4. Chung-Han Lee (3)
  5. Darren Feldman (3)
  6. Jonathan Rosenberg (3)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (6)
  6. 2019 (3)

More Years

Publications
  1. European Urology Oncology (17)
  2. European Urology Open Science (3)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Perioperative serum microRNA 371a-3p and 372-3p levels in patients with clinically localized testicular masses
    Journal Article

    Matulewicz, R. S.; Baky, F.; Knezevic, A.; Sheinfeld, J.; Williams, B. M.; Kantor, R. E.; Liso, N.; Hossain, J.; Bromberg, M.; Valentino, A.; more...
    European Urology Open Science (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer
    Journal Article

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Chaim, J.; Chen, Y.; Jacobi, R.; Zucker, M.; Reznik, E.; McHugh, D.; Shah, N. J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save
  • Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: Analysis of the phase 3 randomized CLEAR Study
    Journal Article

    Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso-Gordoa, T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
    European Urology Oncology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life with adjuvant nivolumab after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 CheckMate 274 trial
    Journal Article

    Witjes, J. A.; Galsky, M. D.; Gschwend, J. E.; Broughton, E.; Braverman, J.; Nasroulah, F.; Maira-Arce, M.; Ye, X. M.; Shi, L.; Guo, S.; more...
    European Urology Oncology (2022)

    Fulltext@MSK | Save
  • First-line systemic treatment of recurrent prostate cancer after primary or salvage local therapy: A systematic review of the literature
    Review

    Weiner, A. B.; Siebert, A. L.; Fenton, S. E.; Abida, W.; Agarwal, N.; Davis, I. D.; Dorff, T. B.; Gleave, M.; James, N. D.; Poon, D. M. C.; more...
    European Urology Oncology (2022)

    Fulltext@MSK | Save
  • Upper tract urothelial carcinoma in the Lynch syndrome tumour spectrum: A comprehensive overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors
    Review

    Lonati, C.; Necchi, A.; Gómez Rivas, J.; Afferi, L.; Laukhtina, E.; Martini, A.; Ventimiglia, E.; Colombo, R.; Gandaglia, G.; Salonia, A.; more...
    European Urology Oncology (2022)

    Fulltext@MSK | Save
  • Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing
    Journal Article

    Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Reisz, P. A.; Lenis, A. T.; Mehta, N. N.; Khurram, A.; Joseph, V.; Mandelker, D.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503)
    Journal Article

    Morris, M. J.; Mota, J. M.; Lacuna, K.; Hilden, P.; Gleave, M.; Carducci, M. A.; Saad, F.; Cohn, E. D.; Filipenko, J.; Heller, G.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma
    Journal Article

    Lee, C. H.; Wan, Y.; Smith, A.; Xie, R.; Motzer, R. J.
    European Urology Open Science (2021)

    Fulltext@MSK | Save

    • Elsevier BV – authorized name for: